This New Finding About Ozempic and Wegovy Could Hurt Novo Nordisk's Stock
NVONovo Nordisk(NVO) The Motley Fool·2024-08-30 18:15

The addressable market for the treatments could potentially contract significantly.Novo Nordisk's (NVO 2.26%) GLP-1 medicines, Ozempic and Wegovy, are bestsellers and household names. Whereas Ozempic is indicated for type 2 diabetes, Wegovy is prescribed for weight loss in the context of obesity. But, if some new information holds true, the company could soon see its presence in both of those markets take a hit.Here's what was just discovered and why it matters.This potential side effect needs urgent invest ...